Málaga Capital
Málaga participates in the trial of the personalised melanoma vaccine
The Regional Hospital and Ibima have included 15 patients in the phase 3 trial of the mRNA vaccine against melanoma.
Latest Ibima news
2 articles
The Biomedical Research Institute of Málaga (IBIMA) has presented its Scientific Report 2025, highlighting its achievements in clinical research.
The Regional Hospital and Ibima have included 15 patients in the phase 3 trial of the mRNA vaccine against melanoma.